The list of the first batch of Chinese medicine price reduction will be released as soon as possible within a month

[although the national development and Reform Commission has not given a clear timetable for the price adjustment for many years, there is no doubt that the first cut of the national traditional Chinese medicine varieties will fall within the year] the long-pending national medical insurance catalog of traditional Chinese medicine varieties will be released this month, the first batch of shortlist, and major varieties such as anti-tumor drugs are expected to lead the decline by more than 25% "The first batch of catalogues has been determined for some time If there is no special situation, the" two sessions "should be officially announced after that, with an average decline of about 25%." Yesterday, an industry authority close to the national development and Reform Commission told the first financial daily The drug price evaluation center of the national development and Reform Commission recently announced that it has completed the price pre evaluation meeting of relevant varieties of Chinese patent medicines in gynecology, ophthalmology, otolaryngology, orthopedics and dermatology, and listened to the expert opinions Moreover, according to the public data, since November 14, 2013, the national development and Reform Commission has held seven intensive price review meetings on Chinese patent medicines, covering all kinds of Chinese patent medicines in the 2010 version of the medical insurance catalog This also means that after the landmark expert review, the price adjustment of related traditional Chinese medicine varieties has entered the release channel At the same time, although the national development and Reform Commission has never given a clear timetable for this multi-year price adjustment, there is no doubt that the first cut of the national traditional Chinese medicine varieties will fall within the year "We are now studying that the price adjustment of traditional Chinese medicine is the key work of this year, and the catalogue will be published in this year." Song Dacai, head of the pricing department of the national development and Reform Commission, said in an interview with the first financial daily on Thursday afternoon In fact, as early as September 2012, the national development and Reform Commission launched the work of reporting and investigating the cost of Chinese patent medicine On February 18, 2012, the evaluation center reviewed four kinds of drugs, namely, digestive, blood, antitumor drugs and immunomodulatory drugs Eight months later, the price of antitumor, immune and blood system drugs dropped by 17%; in early November of that year, the evaluation meeting of psychonarcotic drugs was held On February 30, the policy of reducing the price of 9 kinds of narcotic drugs was introduced immediately It is worth noting that in the past 30 times of drug price reduction, the average decline of the national development and Reform Commission was 15% - 20%, and the maximum decline of some drugs was even about 60%, but the price of traditional Chinese medicine varieties has rarely been reduced "Large varieties such as anti-tumor have been reviewed at the end of last year Last month, the last few varieties should be reviewed and adjusted by experts They will be officially submitted for approval, so they will come out soon." The aforementioned sources told this newspaper According to the price law, the drug administration law and the regulations for the implementation of the drug administration law, at this stage, China has implemented three pricing forms for drugs: government pricing, government guided pricing and enterprise independent pricing At present, there are about 100 kinds of drugs purchased by the government for free and distributed to specific groups, accounting for 0.8% of the approved listed drugs; other drugs are subject to government guided price, with the specific form of the maximum retail price limit, accounting for about 2600 kinds, accounting for about 22%; drugs other than the government guided price and the government guided price are subject to market regulation, and are priced independently by enterprises, accounting for about 77% The government sets and guides prices, and implements a management system at the central and provincial levels Within the above pricing range, there are about 1900 kinds of prescription drugs belonging to the national basic drugs and the national medical insurance catalogue, and the drugs monopolized in production and operation are priced by the national development and Reform Commission The over-the-counter drugs listed in the national medical insurance catalogue and the drugs supplemented by local medical insurance shall be priced by the competent price departments of each province (District, city), about 800 kinds And this price adjustment involves the medical insurance catalog varieties that are most valued by pharmaceutical enterprises and paid by the state According to the public data, in the first half of 2013, the consumption of Chinese patent medicine was 36.63%, that of secondary medical institutions was 41.89%, and that of primary medical institutions was 46.92%; the proportion of tumor drugs in tertiary medical institutions was 18.57%, that of secondary medical institutions was 7.98%, that of primary medical institutions was 7.77%, and that of county-level medical institutions was 6.98% Although the price reduction signal is obvious, enterprises are still looking for other solutions "The cost of traditional Chinese medicine has increased more than ten times in the past five years I hope that the national development and Reform Commission will not cut all the prices of traditional Chinese medicine products Good quality varieties should be protected by price hikes." Xu Shuqing, deputy to the National People's Congress and chairman of Guangxi Wuzhou Zhongheng group, told reporters, "there is still a mechanism for drug prices to reduce prices, not all of them can be eliminated, and good varieties need to be protected." In the interview, many large pharmaceutical enterprises of traditional Chinese medicine, including Jiangsu, Hebei and other places, also said that at present, with the rising cost of raw materials and artificial water and electricity, lowering drug prices will bring negative impact on enterprises and drug safety Prior to that, due to the soaring price of raw material Tianqi caused by successive droughts in Yunnan, Yunnan Baiyao and other related enterprises had requested the development and Reform Commission to approve its price increase plan, and the target price adjustment was even more than 15% In this regard, the relevant person in charge of the national development and Reform Commission has also said on many occasions that the guiding ideology of price adjustment will adhere to the principle of "rising and falling", compress products with excessive profits, and moderately support excellent varieties affected by factors such as raw materials, but how to implement this idea, what methods and formulas should be adopted in the ongoing drug cost investigation to be closest to the actual situation of the enterprise So far, there is no mature program.